Agios Pharmaceuticals, Inc. (8AP)
FSX
27.60
-0.40 (-1.43%)
Real-time Data
06:00 AM
Day's Range
27.6027.60
52 wk Range
19.7038.80
Financial Statements - 8AP - Agios Pharmaceuticals, Inc.
Revenue
54.02M▲ 76.2%
Net Income
-412.78M▼ 172.9%Net Margin -764.0%
EBITDA
-466.95M▲ 63.2%
Free Cash Flow
-387.29M▼ 17.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 54.02M | 30.67M | 26.82M | 14.24M | 0 | 0 |
| Cost of Goods | 6.34M | 3.49M | 2.88M | 1.70M | 0 | 2.80M |
| Gross Profit | 47.68M | 27.17M | 23.94M | 12.53M | 0 | 200.39M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -472.13M | -357.75M | -391.48M | -389.04M | -378.41M | -335.91M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 1.95M | 920.68M | 6.05M | 144.45M | 21.07M | - |
| Pre Tax Income | -413.79M | 603.33M | -352.08M | -231.80M | -356.51M | -329.30M |
| Income Tax | -1.01M | 37.17M | - | - | - | - |
| Net Income | -412.78M | 566.15M | -352.08M | -231.80M | 1.60B | -327.37M |
| EPS Basic | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 | -4.74 |
| EPS Diluted | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 | -4.74 |
| Basic Shares Outstanding | 57.97M | 47.73M | 58.38M | 56.25M | 62.06M | 70.84M |
| Diluted Shares Outstanding | 57.97M | 47.73M | 58.38M | 56.25M | 62.06M | 70.84M |
| Ebit | -472.13M | -357.75M | -391.48M | -389.04M | -378.41M | -335.91M |
| Ebitda | -466.95M | -1.26B | -384.86M | -518.18M | -375.81M | -326.12M |
| Net Income Continuous Operations | -412.78M | 566.15M | -352.08M | -231.80M | -356.51M | -329.30M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
